Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2014-03-03 (12 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VAL-DE-SCIE (76720), Seine-Maritime
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SARL PHARMACIE FRANCOIS : revenue, balance sheet and financial ratios
SARL PHARMACIE FRANCOIS is a French company
founded 12 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VAL-DE-SCIE (76720),
this company of category PME
shows in 2023 a revenue of 2.1 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SARL PHARMACIE FRANCOIS (SIREN 800748881)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
2 055 924 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
94 441 €
86 163 €
82 441 €
163 252 €
123 925 €
135 560 €
87 733 €
133 222 €
134 907 €
87 706 €
EBITDA
N/C
N/C
86 621 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
4.0%
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, SARL PHARMACIE FRANCOIS generates positive net income of 94 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 88 k€ -> 94 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
94 441 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 95%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 46%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
94.958%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
46.22%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
605.359
343.687
218.977
164.286
377.418
262.987
174.364
138.24
109.224
94.958
Financial autonomy
12.871
20.619
29.037
35.048
19.428
25.663
32.103
37.527
43.732
46.22
Repayment capacity
None
None
None
None
None
None
None
9.91
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
4.776%
None%
None%
Sector positioning
Debt ratio
94.962025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of SARL PHARMACIE FRANCOIS (94.96) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
46.22%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average
In 2025, the financial autonomy of SARL PHARMACIE FRANCOIS (46.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
9.91 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of SARL PHARMACIE FRANCOIS (9.91) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 295.30. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
271.502
332.665
374.779
369.125
423.451
504.114
337.879
367.977
360.527
295.295
Interest coverage
None
None
None
None
None
None
None
7.376
None
None
Sector positioning
Liquidity ratio
295.32025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of SARL PHARMACIE FRANCOIS (295.30) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
7.38x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Excellent
In 2023, the interest coverage of SARL PHARMACIE FRANCOIS (7.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SARL PHARMACIE FRANCOIS
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
0 €
158 758 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
0
20
0
0
Customer payment term (days)
0
0
0
0
0
0
0
4
0
0
Supplier payment term (days)
0
0
0
0
0
0
0
33
0
0
Positioning of SARL PHARMACIE FRANCOIS in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SARL PHARMACIE FRANCOIS is estimated at
1 500 206 €
(range 1 018 047€ - 2 354 030€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1018k€1500k€2354k€
1 500 206 €Range: 1 018 047€ - 2 354 030€
NAF 5 année 2025
Valuation method used
Net Income Multiple
94 441 €
×
15.9x
=1 500 207 €
Range: 1 018 047€ - 2 354 031€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SARL PHARMACIE FRANCOIS with other companies in the same sector:
Frequently asked questions about SARL PHARMACIE FRANCOIS
What is the revenue of SARL PHARMACIE FRANCOIS ?
The revenue of SARL PHARMACIE FRANCOIS in 2023 is 2.1 M€.
Is SARL PHARMACIE FRANCOIS profitable?
Yes, SARL PHARMACIE FRANCOIS generated a net profit of 94 k€ in 2025.
Where is the headquarters of SARL PHARMACIE FRANCOIS ?
The headquarters of SARL PHARMACIE FRANCOIS is located in VAL-DE-SCIE (76720), in the department Seine-Maritime.
Where to find the tax return of SARL PHARMACIE FRANCOIS ?
The tax return of SARL PHARMACIE FRANCOIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SARL PHARMACIE FRANCOIS operate?
SARL PHARMACIE FRANCOIS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart